cd19-ucart
B-Cell Acute Lymphoblastic Leukemia
Explore 136 assets in B-Cell Acute Lymphoblastic Leukemia →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Beijing GoBroad Hospital
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06343090CT.gov Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients | — | Recruiting | — | — | — |
NCT06220097CT.gov Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | — | Active Not Recruiting | — | — | — |
NCT04714593CT.gov Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia | — | Unknown | — | — | — |
NCT05333302CT.gov Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | — | Recruiting | — | — | — |
NCT05470777CT.gov CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL | — | Active Not Recruiting | — | — | — |
NCT04166838CT.gov The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) | — | Unknown | — | — | — |
NCT04034446CT.gov CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | — | Terminated | — | — | — |
NCT03671460CT.gov CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | — | Unknown | — | — | — |
NCT03574168CT.gov CD19-CAR-T Cells in Patients With R/R B-ALL | — | Unknown | — | — | — |
NCT03448393CT.gov CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT03064269CT.gov CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | — | Unknown | — | — | — |
NCT02772198CT.gov T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd19-ucart (this asset) | Beijing GoBroad Hospital | P2 | BB · 64 |
| Etoposide | University of Washington | P3 | BBB |
| Vincristine Sulfate | City of Hope Medical Center | P3 | BB |
| Crisantaspase | City of Hope Medical Center | P3 | BB |
| Nivestim | University of Washington | P3 | BB |
| Dasatinib | National Cancer Institute (NCI) | P3 | BB |
| Pegaspargase | National Cancer Institute (NCI) | P3 | BB |
| Mercaptopurine Anhydrous | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | SWOG Cancer Research Network | P3 | BB |
+42 more in the B-Cell Acute Lymphoblastic Leukemia cohort
Other indications for cd19-ucart
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 71 |
| Acute Lymphoblastic Leukemia | — | P2 | B · 63 |
| T-Cell Non-Hodgkin Lymphoma | — | P1/2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd19-ucart in B-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd19-ucart-b-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →